Psychedelic Drugs or Hallucinogens: Exploring Their Medicinal Potential.
Priyanshu Raj, Shyambabu Rauniyar, Bhagyesh Sapkale
Cureus November 1, 2023 DOI: 10.7759/cureus.48719 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Hallucinogens uses Psychedelic drug research Psychedelic drugs Psychedelic medicines Mental health treatment Hallucinogenic therapy Clinical research Drug therapy |
| Citations | 8 |
| Key findings | Serotonergic hallucinogens like LSD and psilocybin show therapeutic potential for neuropsychiatric disorders such as depression, PTSD, and anxiety, and are relatively safer than alcohol. |
Abstract
Serotonergic hallucinogens also referred to as psychedelics, are psychoactive substances that profoundly alter perception, mood, and cognitive processes. These substances, historically intertwined with religious and cultural rituals, offer profound effects that extend beyond mere hallucinations to profoundly altered states of consciousness. Notable compounds like Lysergic acid diethylamide (LSD) and psilocybin, potent in their action on serotonin receptors, play pivotal roles in influencing brain functions. Despite societal misconceptions that have overshadowed their potential, contemporary research increasingly recognizes their therapeutic value. These substances have shown promise in treating neuropsychiatric disorders such as depression, post-traumatic stress disorder (PTSD), and anxiety, leveraging their influence on neuroplasticity. Furthermore, they exhibit therapeutic potential across various conditions, challenging conventional treatment methodologies. Compared to substances like alcohol, traditional psychedelics like LSD and psilocybin emerge as relatively safer substances. The modern revival of scientific interest in psychedelics necessitates a renewed perspective, viewing them not just as recreational entities but as potent therapeutic tools. Harnessing their actual value mandates rigorous scientific investigations and a receptive societal discourse. A re-evaluation of their classification following international criteria is necessary in light of this increasing understanding. Hallucinogens or psychedelic drugs, if used correctly, can potentially be potential treatments for mental illness, signalling a paradigm shift from traditional techniques. To dispel myths and use their therapeutic advantages, embracing this potential necessitates thorough scientific investigation together with an open societal discourse.
Citations in the library
Cited by 4
- Psychedelic therapy - refining the claim of a paradigm shift. International Review of Psychiatry December 1, 2024
- Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review. Psychopharmacology July 1, 2026
- Adolescents’ and Young Adults’ Integration Processes for Extended Difficulties Following Challenging Psychedelic Experiences: A Qualitative Investigation Research Square May 14, 2026
- PTSD Treatment: An Inquiry into the Promising Potential of Psilocybin Journal of Advances in Medicine and Medical Research July 24, 2024
Cites 23
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology April 26, 2017
- Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies Journal of Psychopharmacology September 20, 2010
- Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology March 1, 2015
- Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology December 25, 2017
and 18 more in the library